FBR & Co reiterated their outperform rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a report released on Tuesday morning. The brokerage currently has a $9.00 price objective on the stock.
Other equities research analysts also recently issued reports about the company. Canaccord Genuity set a $10.00 target price on Aurinia Pharmaceuticals and gave the company a buy rating in a report on Friday, August 5th. HC Wainwright lifted their price objective on Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the stock a buy rating in a report on Wednesday, August 17th. Finally, Leerink Swann restated an outperform rating and set a $7.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 6.2943% during midday trading on Tuesday, hitting $3.7203. The stock had a trading volume of 4,765,248 shares. Aurinia Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $4.49. The company has a 50-day moving average price of $2.25 and a 200-day moving average price of $2.74. The company’s market cap is $131.27 million.
An institutional investor recently raised its position in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp raised its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned about 0.29% of Aurinia Pharmaceuticals worth $283,000 as of its most recent filing with the SEC. 20.04% of the stock is owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.